'I was actually offended': Man on Indigenous cancer therapies initially told oncologist wouldn't monitor him

A terminal cancer patient in Saskatchewan believes his choice to be treated using traditional Indigenous medicines rather than chemotherapy was initially disrespected by a specialist in the province, which has since taken action.
Source: CBC | Health - Category: Consumer Health News Tags: News/Canada/Saskatchewan Source Type: news

Related Links:

It was over one hundred years ago that immunotherapy for cancer was first explored by Dr William Coley with the intratumoral injection of bacterial extracts that resulted in tumor regression in select cases. The emergence of surgical procedures, radiation therapy, and chemotherapy eventually became the mainstay of cancer therapies and relegated immune treatments as an unfulfilled pipedream. Nevertheless, it has been apparent that the immune system can play a role in tumor biology as evident by cases of spontaneous tumor regression and increased cancer incidence among immunosuppressed patients.
Source: Surgical Oncology Clinics of North America - Category: Surgery Authors: Tags: Preface Source Type: research
iva Isocitrate dehydrogenases (IDHs) are enzymes that catalyze the oxidative decarboxylation of isocitrate, producing α-ketoglutarate (αKG) and CO2. The discovery of IDH1 and IDH2 mutations in several malignancies has brought to the approval of drugs targeting IDH1/2 mutants in cancers. Here, we summarized findings addressing the impact of IDH mutants in rare pathologies and focused on the relevance of non-mutated IDH enzymes in tumors. Several pieces of evidence suggest that the enzymatic inhibition of IDHs may have therapeutic potentials also in wild-type IDH cancers. Moreover, IDHs inhibition cou...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusions In the span of a very short time—less than a decade—robotic head and neck surgery has transformed the management of the head and neck cancer, and it seems clear that the future of treatment for these cancers lies in a multimodal approach in which TORS is likely to play an important role. Nevertheless, it is important to keep in mind that the current indications for TORS are limited and long-term data on the safety and oncological outcomes are needed to better understand the true role of TORS in treatment of head and neck cancer. Nonetheless, the emergence of ever more advanced robotic instruments i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractGenotoxic anti-cancer therapies such as chemotherapy and radiotherapy can contribute to an increase in second malignancies in cancer survivors due to their oncogenic effects on non-cancerous cells. Inhibition of histone deacetylase (HDAC) proteins or the proteasome differ from chemotherapy in that they eliminate cancer cells by regulating gene expression or cellular protein equilibrium, respectively. As members of these drug classes have been approved for clinical use in recent times, we investigated whether these two drug classes exhibit similar mutagenic capabilities as chemotherapy. The HDAC inhibitors vorinosta...
Source: Apoptosis - Category: Molecular Biology Source Type: research
Conclusion: Our data supports that never/ever smoker patients with small-cell lung cancer have better prognosis compared to their smoker counterparts. Further, patients with never/ever smoking history who present with small-cell lung cancer have a different mutation profile compared with smokers, including a high frequency of EGFR, MET, and SMAD4 mutations. Further studies are required to assess whether the differential mutation profile is a consequence of a diverse pathological mechanism for disease onset. Introduction Lung cancer is the most common neoplasia worldwide. Aside from the high incidence, lung cancer a...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study highlights how the use of in vitro 3D model can allow rapid screening and selection of new and safer drugs. Introduction Angiogenesis is a complex and finely regulated process that consists of the growth of new capillary blood vessels from pre-existing vessels to create communication pathways among tissues. The coordination of different activities such as endothelial cell proliferation and migration, metalloproteinase function, integrin expression and pericyte stabilization is essential for angiogenesis (Folkman, 1984). The “angiogenic switch” is “on” when the balance between pro-...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 15 April 2019Source: European Polymer JournalAuthor(s): Julio César Cuggino, Gerardo Gatti, Matías Luis Picchio, Mariana Maccioni, Luis Marcelino Gugliotta, Cecilia Inés Alvarez IgarzabalAbstractNanocarriers can significantly improve the therapeutic index of drug in cancer therapy. At present, parenteral administration of free doxorubicin (Dox) to treat breast tumor produces severe side effects including cardiotoxicity. This work reports the preparation of N-isopropyacrylamide/acrylic acid nanogels (NGs), NIPA/AAc NGs, crosslinked by a disulfide-bearing monomer, which...
Source: European Polymer Journal - Category: Chemistry Source Type: research
Oral mucositis is a significant complication of cancer therapy because of the associated pain and negative effects on the ability to eat, drink, and swallow and on the quality of life. Furthermore, oral mucositis increases the risk of systemic infection, and may interrupt cancer therapy. Oral mucositis manifests as erosions or ulcerations of the nonkeratinized oral mucosa, and its course depends on the form of cancer therapy. Oral mucositis affects an estimated 14% to 81% of patients undergoing some forms of chemotherapy, begins within days of initiating treatment, and lasts for up to 2 weeks depending on the dose, intensi...
Source: JAMA - Category: General Medicine Source Type: research
Chan Feng1, Donglei Zhu1, Lv Chen1, Yonglin Lu1, Jie Liu1, Na Yoon Kim2, Shujing Liang1, Xia Zhang1, Yun Lin1, Yabin Ma3* and Chunyan Dong1* 1Cancer Center, Shanghai East Hospital, Tongji University, Shanghai, China 2Department of Chemical Engineering, Northeastern University, Boston, MA, United States 3Pharmacy Department, Shanghai East Hospital, Tongji University, Shanghai, China The off-target activation of photosensitizers is one of the most well-known obstacles to effective photodynamic therapy (PDT). The selected activation of photosensitizers in cancer cells is highly desired to overcome this problem. We...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
in N, Serrano I, Midwinter W, Wilk A, Bardaji A, Ingold N, Buchan R, Tayal U, Pascual-Figal DA, de Marvao A, Ahmad M, Garcia-Pinilla JM, Pantazis A, Dominguez F, Baksi AJ, O'Regan DP, Rosen SD, Prasad SK, Lara-Pezzi E, Provencio M, Lyon AR, Alonso-Pulpon L, Cook SA, DePalma SR, Barton PJR, Aplenc R, Seidman JG, Ky B, Ware JS, Seidman CE Abstract BACKGROUND: Cancer therapy-induced cardiomyopathy (CCM) is associated with cumulative drug exposures and pre-existing cardiovascular disorders. These parameters incompletely account for substantial inter-individual susceptibility to CCM. We hypothesized that rare variants ...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Health